Skip to main content

Table 3 ME/CFS symptom characteristics

From: The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients

Age of diagnosis (years [mean ± SEM]) 29.6 ± 3.05
Disease duration (years [mean ± SEM]) 14.93 ± 3.17
Infectious onset, n(%) 13 (86.7%)
Cognitive difficulties
 Yes 15 (100%)
 No 0 (0%)
Pain
 Yes 15 (100%)
 No 0 (0%)
Sleep disturbances
 Yes 15 (100%)
 No 0 (0%)
Sensory disturbances
 Yes 15 (100%)
 No 0 (0%)
Immune disturbances
 Yes 14 (93.3%)
 No 1 (6.7%)
Gastrointestinal disturbances
 Yes 14 (93.3%)
 No 1 (6.7%)
Cardiovascular disturbances
 Yes 15 (100%)
 No 0 (0%)
Respiratory disturbances
 Yes 8 (53.3%)
 No 7 (46.7%)
Thermostatic instability
 Yes 11 (73.3%)
 No 4 (26.7%)
Urinary disturbances
 Yes 5 (33.3%)
 No 10 (66.7%)
  1. ME Myalgic encephalomyelitis, CFS chronic fatigue syndrome, SEM standard error of mean, n number